Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence

Cancer Research

Volumn 71, Issue 19, 2011, Pages 6184-6194

  Bitler, Benjamin G ^a   Nicodemus, Jasmine P ^a   Li, Hua ^a   Cai, Qi ^a   Wu, Hong ^a   Hua, Xiang ^a   Li, Tianyu ^a   Birrer, Michael J ^b   Godwin, Andrew K ^c   Cairns, Paul ^a   Zhang, Rugang ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; WNT PROTEIN; WNT5A PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STAGING; CELL AGING; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; SIGNAL TRANSDUCTION; UTERINE TUBE;

ANIMALS; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; FALLOPIAN TUBES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PROTO-ONCOGENE PROTEINS; WNT PROTEINS;

EID: 80053361798     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1341     Document Type: Article

References (49)

1. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010;24:2463-79.
2. Adams PD. Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. Mol Cell 2009;36:2-14.
3. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
4. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007;445:661-5. (Pubitemid 46232887)
5. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60. (Pubitemid 46232886)
6. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010;102:1536-46.
7. Peeper DS. PICS-ure this: prosenescence therapy? Cancer Cell 2010;17:219-20.
8. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24. (Pubitemid 38121593)
9. Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res 2008;18:538-48. 10. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-8.
10. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691-701. (Pubitemid 39150127)
11. Katoh M.WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007;13:4042-5. (Pubitemid 47105963)
12. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A 1999;96:1603-8. (Pubitemid 29098498)
13. Szotek PP, Chang HL, Brennand K, Fujino A, Pieretti-Vanmarcke R, Lo Celso C, et al. Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci U S A 2008;105:12469-73.
14. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11:321-33. (Pubitemid 46518315)
15. McDonald SL, Silver A. The opposing roles of Wnt-5a in cancer. Br J Cancer 2009;101:209-14.
16. Li H, Cai Q, Godwin AK, Zhang R. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res 2010;8:1610-8.
17. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 2006;66: 5021-8. (Pubitemid 43844922)
18. Zhang R, Chen W, Adams PD. Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol 2007; 27:2343-58. (Pubitemid 46418486)
19. Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 2005;8:19-30. (Pubitemid 40058002)
20. Cheyette BN, Waxman JS, Miller JR, Takemaru K, Sheldahl LC, Khlebtsova N, et al. Dapper, a Dishevelled-associated antagonist of beta-catenin and JNK signaling, is required for notochord formation. Dev Cell 2002;2:449-61. (Pubitemid 34436574)
21. Ye X, Zerlanko B, Kennedy A, Banumathy G, Zhang R, Adams PD. Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell 2007;27:183-96. (Pubitemid 47058300)
22. Itahana K, Campisi J, Dimri GP. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol Biol 2007;371:21-31. (Pubitemid 350183415)
23. Connolly DC, Hensley HH. Xenograft and transgenic mouse models of epithelial ovarian cancer and non invasive imaging modalities to monitor ovarian tumor growth in situ - applications in evaluating novel therapeutic agents. Curr Protoc Pharmacol 2009;45:14.12.1-26.
24. Kurman RJ, Shih le M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
25. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986;46: 4244s-8s. (Pubitemid 16041242)
26. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133: 1710-5. (Pubitemid 14035254)
27. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96. (Pubitemid 27435555)
28. Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, Bradley A, et al. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 2003;4:349-60. (Pubitemid 37491096)
29. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits betacatenin- TCF signaling depending on receptor context. PLoS Biol 2006;4:e115.
30. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, Yang Y. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 2003;162:899-908. (Pubitemid 37087729)
31. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50. (Pubitemid 40558990)
32. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 2007;8:1006-16. (Pubitemid 350174636)
33. Mallette FA, Goumard S, Gaumont-Leclerc MF, Moiseeva O, Ferbeyre G. Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene 2004;23:91-9. (Pubitemid 38142243)
34. Ferbeyre G, De Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 2000;14:2015-27. (Pubitemid 30637352)
35. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell 2002;108:165-70. (Pubitemid 34161137)
36. Ye X, Zerlanko B, Zhang R, Somaiah N, Lipinski M, Salomoni P, et al. Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol 2007;27:2452-65. (Pubitemid 46581338)
37. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000;406:207-10. (Pubitemid 30469006)
38. Watson JE, Gabra H, Taylor KJ, Rabiasz GJ, Morrison H, Perry P, et al. Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis. Genome Res 1999;9:226-33. (Pubitemid 29168185)
39. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998;18:753-61. (Pubitemid 28063408)
40. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992;52:4196-9.
41. Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010;120:681-93.
42. Collado M. Exploring a 'pro-senescence' approach for prostate cancer therapy by targeting PTEN. Future Oncol 2010;6:687-9.
43. Safholm A, Tuomela J, Rosenkvist J, Dejmek J, Harkonen P, Andersson T. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res 2008;14:6556-63.
44. Pukrop T, Binder C. The complex pathways of Wnt 5a in cancer progression. J Mol Med 2008;86:259-66. (Pubitemid 351311422)
45. Li J, Ying J, Fan Y, Wu L, Ying Y, Chan AT, et al. WNT5A antagonizes WNT/beta-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther 2007;10:617-24.
46. Nishita M, Enomoto M, Yamagata K, Minami Y. Cell/tissue-tropic functions of Wnt5a signaling in normal and cancer cells. Trends Cell Biol 2010;20:346-54.
47. Badiglian Filho L, Oshima CT, De Oliveira Lima F, De Oliveira Costa H, De Sousa Damiao R, Gomes TS, et al. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep 2009;21:313-20.
48. Peng C, Zhang X, Yu H, Wu D, Zheng J. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int J Gynecol Cancer 2011;21:280-8.
49. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 2009;16:521-32.